CLINICAL TRIALS PROFILE FOR AZD4831
✉ Email this page to a colleague
Clinical Trials for AZD4831
| Trial ID | Title | Status | Sponsor | Phase | Summary |
|---|---|---|---|---|---|
| NCT02712372 ↗ | A Study to Assess the Safety and Tolerability of Single and Multiple Doses of AZD4831 in Healthy Male Subjects | Terminated | AstraZeneca | Phase 1 | This is a Phase I, first-in-human (FIH) study to assess the safety, tolerability, pharmacokinetics (PK) and Pharmacodynamics (PD) of AZD4831 after single and multiple ascending doses in healthy male subjects |
| NCT03136991 ↗ | A Phase I, Safety Tolerability and Pharmacokinetics of AZD4831 to Treat Cardiovascular Disease | Completed | Parexel | Phase 1 | This is a Phase I study to investigate the safety and tolerability of AZD4831 in healthy male participants, conducted at a single center. The results from this study will form the basis for decisions on future studies. Another purpose of this dose escalation study is to find out the right dose of the experimental drug to be given to study participants in future studies. Even though there were no harmful effects seen in the animals tested, investigator does not know what side effects the experimental drug might cause in humans. However, site personnel managing the study participants will be blinded to the extent possible and as long as possible to minimize any impact on data collection. Study participants will be blinded to treatment allocation. The study will be conducted in healthy participants to avoid interference from disease processes or other drugs. The participants will stay at the study center during the whole dosing period and until 48 hours post final dose. |
| NCT03136991 ↗ | A Phase I, Safety Tolerability and Pharmacokinetics of AZD4831 to Treat Cardiovascular Disease | Completed | AstraZeneca | Phase 1 | This is a Phase I study to investigate the safety and tolerability of AZD4831 in healthy male participants, conducted at a single center. The results from this study will form the basis for decisions on future studies. Another purpose of this dose escalation study is to find out the right dose of the experimental drug to be given to study participants in future studies. Even though there were no harmful effects seen in the animals tested, investigator does not know what side effects the experimental drug might cause in humans. However, site personnel managing the study participants will be blinded to the extent possible and as long as possible to minimize any impact on data collection. Study participants will be blinded to treatment allocation. The study will be conducted in healthy participants to avoid interference from disease processes or other drugs. The participants will stay at the study center during the whole dosing period and until 48 hours post final dose. |
| NCT03611153 ↗ | MPO Inhibitor A_Zeneca for HFpEF | Recruiting | Mayo Clinic | Phase 1/Phase 2 | Researchers are studying the effect of a single dose of oral myeloperoxidase on heart failure versus placebo. |
| NCT03756285 ↗ | Safety and Tolerability Study of AZD4831 in Patients With Heart Failure. | Terminated | AstraZeneca | Phase 2 | A randomized, double-blind, placebo-controlled, parallel group, multicentre study in patients with Heart Failure with preserved Ejection Fraction (HFpEF). The study will be conducted at approximately 15 sites in 5 countries. Approximately 96 patients will be randomized to AZD4831 or placebo (treatment duration 90 days). |
| NCT04232345 ↗ | A Study to Assess the Effect AZD4831 in Japanese and Chinese Healthy Volunteers | Completed | Parexel | Phase 1 | This study is randomized, single-blind, placebo-controlled Phase 1 study aimed to assess the safety and efficacy, pharmacokinetics and pharmacodynamics of multiple doses of oral AZD4831 in healthy Japanese and Chinese volunteers |
| NCT04232345 ↗ | A Study to Assess the Effect AZD4831 in Japanese and Chinese Healthy Volunteers | Completed | AstraZeneca | Phase 1 | This study is randomized, single-blind, placebo-controlled Phase 1 study aimed to assess the safety and efficacy, pharmacokinetics and pharmacodynamics of multiple doses of oral AZD4831 in healthy Japanese and Chinese volunteers |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Summary |
Clinical Trial Conditions for AZD4831
Condition Name
Clinical Trial Locations for AZD4831
Trials by Country
Clinical Trial Progress for AZD4831
Clinical Trial Phase
Clinical Trial Sponsors for AZD4831
Sponsor Name
